Beranda › Penyakit Paru › New Jersey
Uji klinis Penyakit Paru di New Jersey
6 studi untuk Penyakit Paru mencari peserta di lokasi di New Jersey.
Kota di New Jersey
Teks studi resmi (Bahasa Inggris)
A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised
- Holy Name Medical Center, Teaneck
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT07013474A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma
- Rutgers, Robert Wood Johnson Medical School, New Brunswick
- Circuit Clinical / Impact Medical Allergy, Asthma & Immunology, Riverdale
Menerima pesertaFase 2
Usia 18 hingga 70 · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT06977581A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- The Valley Hospital, Inc., Paramus
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT06119581A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.
- Memorial Sloan Kettering Cancer Center - Basking Ridge, Basking Ridge
- Memorial Sloan Kettering Cancer Center - Monmouth, Middletown
- Memorial Sloan Kettering Cancer Center - Bergen, Montvale
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Sep 2026 · NCT05967689Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
- MD Anderson Cooper, Camden
Menerima pesertaFase 2
Usia 18 hingga 70 · Semua jenis kelamin · Diperbarui 26 Jun 2026 · NCT04614103TELEhealth Shared Decision-making COaching for Lung Cancer Screening in Primary Care (TELESCOPE) for Hispanics
- Rutgers Cancer Institute, New Brunswick
Menerima pesertaSukarelawan sehat diterima
Usia 50 hingga 77 · Semua jenis kelamin · Diperbarui 2 Des 2025 · NCT07165691Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.